Balance Sheet
Cash Flow Statement
AmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MediWound (MDWD) Change in Working Capital (2016 - 2022)

MediWound has reported Change in Working Capital over the past 10 years, most recently at $404000.0 for Q3 2022.

  • For Q3 2022, Change in Working Capital fell 9.42% year-over-year to $404000.0; the TTM value through Sep 2022 reached $404000.0, down 9.42%, while the annual FY2024 figure was $770000.0, 64.53% up from the prior year.
  • Change in Working Capital for Q3 2022 was $404000.0 at MediWound, up from $272000.0 in the prior quarter.
  • Over five years, Change in Working Capital peaked at $1.7 million in Q3 2018 and troughed at -$991000.0 in Q4 2020.
  • A 5-year average of $538066.7 and a median of $404000.0 in 2022 define the central range for Change in Working Capital.
  • Biggest five-year swings in Change in Working Capital: increased 18.88% in 2019 and later plummeted 73.68% in 2020.
  • Year by year, Change in Working Capital stood at $1.7 million in 2018, then fell by 10.33% to $1.5 million in 2019, then plummeted by 165.24% to -$991000.0 in 2020, then surged by 145.01% to $446000.0 in 2021, then decreased by 9.42% to $404000.0 in 2022.
  • Business Quant data shows Change in Working Capital for MDWD at $404000.0 in Q3 2022, $272000.0 in Q2 2022, and $446000.0 in Q3 2021.